Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Lingotto Innovation’s James Anderson and Morgan Samet favor companies with explosive growth potential and a focus on ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Today, Zacks Investment Ideas feature highlights Palantir PLTR, Tempus AI TEM and Comfort Systems USA FIX. These 3 AI-Relate ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price... On Tuesday, Stifel, a brokerage firm, initiated coverage on ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...